Tag: DOLV

Blue Horseshoe Stocks: BBRY Recap, AEMD & More

Blackberry Ltd. BBRY – Options Review

We were very confident in the options ideas we formulated for BBRY in yesterday’s premarket report, which were the BBRY Weekly $9.50 & $10 Calls.  We pointed to the company’s convincing earnings beat as being the reason we felt a solid move was in order, despite the fact that it had just been hanging around the $9 area without a lot of volatility for the preceding few weeks.

A solid move is exactly what we got, with BBRY stock running from 9.78 to 10.83 on the day. That facilitated some fantastic gain opportunities for anyone who was following along with our ideas, which both produced multi-bag intraday upswings.

The $9.50 Calls traded in a range from .37-1.26 for a gain of 240%, while the $10’s ripped extremely hard from a low of .12 all the way up to .76. That worked out to an increase of 533% marking the second consecutive week where we’ve alerted on an options idea and seen a single-session gain of over 500% (KMX, last Friday).

Important Note: Never trade options with a weekly expiration on a Friday unless you’re an expert trader with disposable funds. It’s extremely risky.

Aethlon Medical, Inc. AEMD

The other top performer from yesterday’s premarket newsletter was AEMD, which, as you can see from the included chart snapshot, we alerted at the absolute perfect time. The stock had practically been in free-fall over the past couple of weeks, and we signaled the bottom with precision.

It traded in a range from 1.18 to 1.70, for a respectable intraday increase of 44% and closed at the high of day. This is a stock that was trading at nearly $4 just this month, and now we’re going to be monitoring to see how much of that ground it can recapture on the rebound. We’ll look for it to establish higher highs and higher lows. If it can manage to crack through the channel between the current 50DMA of 1.75 and September 11th’s swing high of 2.00, things could once again get very interesting for AEMD.

Extended Watchlist:
HMNY, VERI, ADHD, CONN, ZYNE, VKTX, DOLV

Blue Horseshoe Stocks: Options Roundup & More

Options Roundup

We had good fortune with our fresh options call yesterday, so today we’re going to be recapping the total possible gains on those plays, as well as unearthing a couple of fresh ideas to add to the mix as we close out this trading week.

Delta Air Lines, Inc. DAL – Recap – Our inkling on DAL yesterday morning was to go bearish after a disappointing earnings call for the airline, with the DAL Weekly $55.50-53.50 Puts. We were not disappointed with our decision to do so, as those DAL puts went on to log the following double and multi-bag intraday moves for us before lunch hour was over:

$55.50 Puts – Range: .76-1.60 – Max Gain: 110%
$55 Puts – Range: .48-1.05 – Max Gain: 119%
$54.50 Puts – Range: .25-.65 – Max Gain: 160%
$54 Puts – Range: .13-.36 – Max Gain: 177%
$53.50 Calls – Range: .03-.17 – Max Gain: 466%
______

Advanced Micro Devices Inc. AMD

Speaking of bearish options ideas, we want to enter another fresh set into the log this morning in AMD. This stock trades very cyclically, and from a technical perspective, looks as if it could continue to lose ground after a reversal this week. We’re going to place the AMD 07/21 $14-13 Puts on watch into next week in the event that our impression of this play is correct.
______

BJ’s Restaurants, Inc. BJRI

Lastly on the options front, we are going to signal a range of extended-term calls on BJRI, which has a pretty attractive bottom setup on the chart at the moment. To take advantage of a potential sustained rebound, we’re going to be monitoring the BJRI 08/18 $35 & 40 Calls.
_____

Bonus Idea: NTNX 7/21 $20-25 Calls

Diana Containerships. Inc. DCIX

DCIX went into a full-on nose dive recently after it was announced that the company would be taking out roughly an $85M loan to settle a monster pile of debt, and the investment community did not take the news well.

The stock has subsequently fallen to new all-time lows, and that’s where we come in. We’re always looking for stocks like this to put on bottom-watch. Being egregiously oversold, DCIX may yet have a bit further to fall, but we’ll want to be ready for a reversal at any time. The resulting bounce-back could be considerable.

Extended Watchlist:
NPHC, DEWM, DOLV, FRO, JCP, CHFS, PIXY, HPJ, CTIC,

Blue Horseshoe Stocks: Options, Bottom-Plays & More

Dollar General Corp. DG – Recap

After a beat on sales and profits for the quarter and a chart primed for a bullish move, we highlighted the DG Weekly $75-78 Calls and we’re happy to report that each and every one of the contracts contained within that range recorded huge intraday moves for us.

Regardless which set of the seven was chosen, multi-bag gains were there for the taking:

$75 Calls – Range: .92-3.10 – Max Gain: 237%
$75.50 Calls – Range: .64-.2.22 – Max Gain: 247%
$76 Calls – Range: .40-2.05 – Max Gain: 412%
$76.50 Calls – Range: .24-1.20 – Max Gain: 400%
$77 Calls – Range: .12-1.21 – Max Gain: 908%
$77.50 Calls – Range: .06-.80 – Max Gain: 1233%
$78 Calls – Range: .05-.45 – Max Gain: 800%

_______

Lululemon Athletica LULU – Fresh Ideas

Lululemon had an earnings beat of its own yesterday post-market, so we want to formulate some ideas for the LULU chain as well.

Not only is the stock gapping up on earnings, but like DG yesterday, the LULU chart was already looking like a bottom-play with premium potential. That’s why we want to formulate both a short and long term set of ideas for LULU options. The LULU Weekly $55-57.50 Calls*, to coincide with the immediate boost in activity off of these earnings, and the LULU 06/30 58.50-60.50 Calls in the event of a protracted recovery.

*We never highlight options with a weekly expiration on a Friday without an explicit warning. That should tell you how risky it can be. So if you’re not an expert trader, don’t even think about it!

Synergy Pharmaceuticals, Inc. SGYP

We also want to put SGYP on watch today after noticing that the stock is coming off of its 52-week lows. That’s always a chart setup that we’re going to look at, but in this case the lows followed shartly after the company producing positive Phase III data on its TRULANCE™ drug, which is already approved by the FDA.

We’ve included a chart snapshot here, and you can plainly see, the stock had been beaten back severely and is only just now beginning to mount a rebound.

Extended Watchlist:
DOLV, USRM, ICNB, ANW, CGG, ANTH